Astellas is to work with UK biotech Adaptimmune Therapeutics to develop allogeneic ‘off-the-shelf’ T-cell therapies for cancer. The Japanese pharma said its wholly-owned subsidiary Universal ...

Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working to redefine the treatment of solid tumor cancers with cell therapy, today announced presence and presentations at key scientific and ...

Adaptimmune Therapeutics plc (NASDAQ:ADAP – Get Free Report) was the recipient of a significant decline in short interest during the month of October.As of October 15th, there was short interest ...

NASDAQ:ADAP opened at $0.87 on Monday. Adaptimmune Therapeutics has a 12 month low of $0.42 and a 12 month high of $2.05. The company has a current ratio of 3.09, a quick ratio of 3.09 and a debt ...

In this article, we are going to take a look at where Adaptimmune Therapeutics plc (NASDAQ:ADAP) stands against the other one-dollar stocks. The upward trend in the stock market has resumed ...

Short interest in Adaptimmune Therapeutics PLC (NASDAQ:ADAP) decreased during the last reporting period, falling from 6.09M to 5.56M. This put 3.26% of the company's publicly available shares short.

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on HCA Healthcare (HCA – Research Report), ...

Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - November 5, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working to redefine the treatment of solid tumor ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

View Adaptimmune Therapeutics plc (ADAP) current and estimated P/E ratio data provided by Seeking Alpha.